Halozyme's Royalty Engine Accelerates, But Transformation to Delivery Toll Road Carries Risks

What happened

Halozyme's FY2025 royalty revenue surged 52% to $867.8M, and 2026 guidance calls for 30–35% royalty growth and adjusted EBITDA of $1.125–$1.205B, as the company evolves from an ENHANZE royalty story into a diversified subcutaneous drug delivery platform. Recent acquisitions of Hypercon and Surf Bio, along with new partnerships with Vertex and Takeda, extend its IP runway and position it as a one-stop biologic delivery solutions provider. However, the DeepValue Master Report flags that the stock trades ~33% above a DCF estimate of $49.46, core ENHANZE patents start expiring in 2027, and aggressive leveraged M&A (including the potential Evotec deal) adds integration risk. While the business quality justifies a premium, the margin of safety looks thin with debt maturities approaching and partner concentration high. The positive news does not resolve the fundamental tension between strong current cash flows and looming structural uncertainties.

Implication

Halozyme is building a durable drug-delivery franchise, but investors should require evidence that ENHANZE economics persist post-2027, debt is refinanced smoothly, and acquired platforms generate clear returns before committing capital at current elevated multiples.

Thesis delta

The accelerating royalty growth and platform expansion reinforce the bull case, but they do not materially alter the risk/reward calculus. The core thesis remains 'wait' until the IP cliff, high leverage, and M&A execution risks are resolved or discounted by a lower share price.